Biotech entity
America First Policy Institute is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window. That works out to roughly 0.2 stories per week across a 170-day span.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
America First Policy Institute is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3.5 for the same window. That works out to roughly 0.2 stories per week across a 170-day span. The 6.8 average consequence score is above the beat benchmark of 6.1 in the same window. fda-approval accounts for 2 of the 4 tracked stories, while 1 other category carries the remainder. We currently track 4 Biotech stories that mention Marty Makary, published between March 4, 2026 and August 20, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 623 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Marty Makary. Shared-story counts are live from our verified record — not editorial picks.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
Marty Makary resigns as FDA Commissioner
The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.
Initial Inquiry
The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
Investigation Announced
Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
Commissioner Meeting
Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.
For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Source: MedPage Today · Kstp Television
Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability.
Source: nbcwashington.com · kfbk.iheart.com
Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
Marty Makary is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
